astria therapeutics glp-1 receptor agonist weight management diabetes treatments Evolution of GLP‐1 Agonists for Treatment How GLP-1 Receptor Agonists Evolved

Likely, multiple mechanisms contribute

In a 10-week clinical trial, a daily dose of 20 mg oral semaglutide achieved a steady-state plasma concentration of 30 nM, and when daily dose of oral semaglutide was increased to 40 mg, the semaglutide plasma concentration reached about 60 nM (102), which was over a thousand times higher than the EC50 of semaglutide for GLP-1R activation (95)

Reduced appetite makes it easier to make better food choices without fighting constant hunger

doi:10.1016/j.cgh.2023.08.034 70

In addition, all currently available GLP-1R therapies are peptide agonists, most of which require subcutaneous administration [140]